Investors info on companies web page22 Jan 2022 20:14
Nothing on telly so to speak so I thought i`d look on Avactas web page and in particular on their Investors page and i`ve copied the paragraph and posted below.
Doxorubicin is a $1bn generic drug and a standard of care for many soft tissue sarcomas despite severe cardiotoxicity issues that limits its effectiveness. In the case of Avacta’s improved version of this drug, AVA6000 pro-Doxorubicin that incorporates the pre|CISIONTM tumour targeting technology, a dramatic improvement in safety has been observed in pre-clinical animal models. If a similar reduction in cardiotoxicity is seen in humans in the phase I clinical trial of AVA6000, then there is the potential for a major license deal that could generate a transformational, non-dilutive, upfront payment of tens of millions of dollars. This funding would support all Avacta’s other programmes in future. The pre|CISIONTM technology to improve the safety of a large number of other established chemotherapies and generate similar licensing opportunities. For this reason, the Company is prioritising this programme.
The Group also benefits from revenue generating businesses in the human and veterinary diagnostics market.
2 things that I didn`t realise before.
1, if they can prove AVA6000 is somewhat successful and less toxic, funding and millions of £s will keep the company going.
mouthwatering and with recent news, there a chance we could be looking rosie !
2, where did vetinery applications come into the factor, all seems very logical but no one has mentioned this before.
avacta really seems to be spreading its wings.
next week or two could be very interesting
Kong
Sign In
Follow the stocks
